3BBLACKBIO vs BALAXI: Stock Comparison

3B Blackbio DX Ltd vs BALAXI PHARMACEUTICALS LIMITED

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

3B Blackbio DX Ltd is the larger company by market capitalisation. 3B Blackbio DX Ltd shows a higher ROE, a higher dividend yield and faster revenue growth, while BALAXI PHARMACEUTICALS LIMITED shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of 3B Blackbio DX Ltd and BALAXI PHARMACEUTICALS LIMITED on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, 3BBLACKBIO is more favourable on 11 of 13 scored metrics and BALAXI on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
3BBLACKBIO is the larger company
₹1,098 Cr vs ₹135 Cr
P/E Ratio
BALAXI has a lower P/E
12.63x vs 19x
P/B Ratio
BALAXI has a lower P/B
0x vs 3.43x
EPS
3BBLACKBIO has higher earnings per share
₹68.3 vs ₹1.72
Dividend Yield
3BBLACKBIO has a higher dividend yield
0.34% vs 0%
Revenue Growth (TTM YoY)
3BBLACKBIO has faster revenue growth
0% vs -25.76%
EPS Growth (TTM YoY)
3BBLACKBIO has faster EPS growth
0% vs -58.44%
Qtr Sales Growth
3BBLACKBIO has stronger quarterly sales growth
57.5% vs 7.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

Metric3BBLACKBIOBALAXI
SectorHealthcare
IndustryPharmaceuticals

Price

Metric3BBLACKBIOBALAXI
Live Price₹1,298.8₹24.44
Day Change0.5%0.21%
Volume10,69422,411
52-Week High₹1,441.5₹52.5
52-Week Low₹1,085₹15.2
Distance from 52W High-9.9%-53.45%

Valuation

Metric3BBLACKBIOBALAXI
Market Cap₹1,098 Cr₹135 Cr
P/E Ratio19x12.63x
P/B Ratio3.43x0x
EPS₹68.3₹1.72
Book Value₹378₹41.98
Dividend Yield0.34%0%

Growth

Metric3BBLACKBIOBALAXI
Revenue Growth (TTM YoY)0%-25.76%
EPS Growth (TTM YoY)0%-58.44%
Qtr Sales Growth57.5%7.8%
Qtr Profit Growth13.8%-95.5%

Profitability & Leverage

Metric3BBLACKBIOBALAXI
ROE19.8%0.57%
ROCE25.5%13%
Net Margin42.23%0.52%
Operating Margin40%3.4%
Debt to Equity0.01x0.22x

Shareholding

As of Mar 2026 • change vs previous quarter
Metric3BBLACKBIOBALAXI
Promoter Holding38.46%65.99%
FII Holding2.57%0%
DII Holding1.98% 0.1 pp2.56%
Public Holding54.51% 0.23 pp31.45%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: 3B Blackbio DX Ltd and BALAXI PHARMACEUTICALS LIMITED.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.